Cyto­tox­ic NK Cells Impede Response to Check­point Immunother­a­py in Melanoma with an Immune-Exclud­ed Phenotype

Joan­na Poz­ni­ak, Nic­colò Roda, Ewout Lan­de­loos, Asi­er Antoranz, Yan­nick Van Her­ck, Amber De Viss­ch­er, Philip Georg Demaer­el, Lukas Van­wyns­berghe, Jeroen Decler­cq, Chris­tos Gkemi­sis, Greet Bervoets, Ayse Bassez, Robin Browaeys, Lotte Pol­laris , Francesca M. Bosi­sio, Veer­le Boecxs­taens, Yvan Saeys, Diether Lam­brechts, Patrick Matthys, Oliv­er Bechter & Jean-Christophe Marine

Immune check­point block­ade (ICB) tar­get­ing PD‑1 has trans­formed melanoma ther­a­py, yet half of patients do not ben­e­fit, often due to unclear resis­tance mech­a­nisms. Immune exclu­sion-the inabil­i­ty of lym­pho­cytes to enter the tumor nest-is a key bar­ri­er, and stud­ies using only base­line or late post-treat­ment sam­ples may miss ear­ly immune dynamics.

We hypoth­e­sized that treat­ment-induced changes occur after a sin­gle ICB cycle. In an inter­ven­tion­al study, we pro­filed melanoma with sin­gle-cell RNA-seq, ana­lyz­ing 46 tumor sam­ples from 23 patients, includ­ing 20 matched pre- and ear­ly on-treat­ment biop­sies. We iden­ti­fied 20 immune cell types and linked their abun­dance to response. Con­sis­tent with pri­or work, respon­ders were enriched for CD8+ T cell sub­sets, par­tic­u­lar­ly CD8+ CXCL13+ T cells, at both time­points. Sur­pris­ing­ly, cyto­tox­ic nat­ur­al killer (NK) cells were sig­nif­i­cant­ly enriched in non-respon­ders ear­ly on treat­ment, val­i­dat­ed in two inde­pen­dent melanoma cohorts and one breast can­cer scR­NA-seq cohort.

Spa­tial tran­scrip­tom­ic and pro­teom­ic analy­ses from the same lesions showed that in non-respon­ders, NK and CD8+ T cells co-accu­mu­lat­ed at the tumor rim but failed to pen­e­trate the core, con­sis­tent with immune exclu­sion; respond­ing tumors showed co-local­iza­tion with­in the parenchy­ma. In an immune-exclud­ed mouse melanoma mod­el, phar­ma­co­log­ic NK cell deple­tion enhanced CD8+ T cell infil­tra­tion into the core and enabled tumor clear­ance with anti-PD‑1. Mech­a­nis­ti­cal­ly, NK cells were recruit­ed to exclud­ed regions via CX3CR1 and con­strained CD8+ T cell infil­tra­tion and func­tion. These find­ings iden­ti­fy an unex­pect­ed NK cell – medi­at­ed resis­tance axis and sug­gest tar­get­ing NK recruit­ment or activ­i­ty to over­come immune exclu­sion and improve ICB responses.

Joan­na Poz­ni­ak, Nic­colò Roda, Ewout Lan­de­loos, Asi­er Antoranz, Yan­nick Van Her­ck, Amber De Viss­ch­er, Philip Georg Demaer­el, Lukas Van­wyns­berghe, Jeroen Decler­cq, Chris­tos Gkemi­sis, Greet Bervoets, Ayse Bassez, Robin Browaeys, Lotte Pol­laris , Francesca M. Bosi­sio, Veer­le Boecxs­taens, Yvan Saeys, Diether Lam­brechts, Patrick Matthys, Oliv­er Bechter & Jean-Christophe Marine

Immune check­point block­ade (ICB) tar­get­ing PD‑1 has trans­formed melanoma ther­a­py, yet half of patients do not ben­e­fit, often due to unclear resis­tance mech­a­nisms. Immune exclu­sion-the inabil­i­ty of lym­pho­cytes to enter the tumor nest-is a key bar­ri­er, and stud­ies using only base­line or late post-treat­ment sam­ples may miss ear­ly immune dynamics.

We hypoth­e­sized that treat­ment-induced changes occur after a sin­gle ICB cycle. In an inter­ven­tion­al study, we pro­filed melanoma with sin­gle-cell RNA-seq, ana­lyz­ing 46 tumor sam­ples from 23 patients, includ­ing 20 matched pre- and ear­ly on-treat­ment biop­sies. We iden­ti­fied 20 immune cell types and linked their abun­dance to response. Con­sis­tent with pri­or work, respon­ders were enriched for CD8+ T cell sub­sets, par­tic­u­lar­ly CD8+ CXCL13+ T cells, at both time­points. Sur­pris­ing­ly, cyto­tox­ic nat­ur­al killer (NK) cells were sig­nif­i­cant­ly enriched in non-respon­ders ear­ly on treat­ment, val­i­dat­ed in two inde­pen­dent melanoma cohorts and one breast can­cer scR­NA-seq cohort.

Spa­tial tran­scrip­tom­ic and pro­teom­ic analy­ses from the same lesions showed that in non-respon­ders, NK and CD8+ T cells co-accu­mu­lat­ed at the tumor rim but failed to pen­e­trate the core, con­sis­tent with immune exclu­sion; respond­ing tumors showed co-local­iza­tion with­in the parenchy­ma. In an immune-exclud­ed mouse melanoma mod­el, phar­ma­co­log­ic NK cell deple­tion enhanced CD8+ T cell infil­tra­tion into the core and enabled tumor clear­ance with anti-PD‑1. Mech­a­nis­ti­cal­ly, NK cells were recruit­ed to exclud­ed regions via CX3CR1 and con­strained CD8+ T cell infil­tra­tion and func­tion. These find­ings iden­ti­fy an unex­pect­ed NK cell – medi­at­ed resis­tance axis and sug­gest tar­get­ing NK recruit­ment or activ­i­ty to over­come immune exclu­sion and improve ICB responses.

Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype

Joan­na Poźniak

Joan­na holds a Bachelor’s degree in Mol­e­c­u­lar Biol­o­gy and an inter­na­tion­al Master’s degree in Biotech­nol­o­gy from Adam Mick­iewicz Uni­ver­si­ty in Poz­nań, Poland. She com­plet­ed her PhD at the Uni­ver­si­ty of Leeds as part of the Marie Skłodows­ka-Curie Ear­ly Train­ing Net­work (MEL­GEN), where her research focused on char­ac­ter­iz­ing immune infil­tra­tion across a large cohort of pri­ma­ry melanoma tran­scrip­tomes using bioin­for­mat­ics and sta­tis­ti­cal approaches. 

She is cur­rent­ly a Senior Post­doc­tor­al Researcher in Bioin­for­mat­ics at the Marine Lab (VIB – KU Leu­ven, Bel­gium), sup­port­ed by Marie Skłodows­ka-Curie and STK Bel­gian fel­low­ships. Her work focus­es on melanoma het­ero­gene­ity and respons­es to immunother­a­py, employ­ing sin­gle-cell sequenc­ing and spa­tial tran­scrip­tomics. Her con­tri­bu­tions have been rec­og­nized with the pres­ti­gious Soci­ety for Melanoma Research (SMR) Young Inves­ti­ga­tor Award.

More about Dr. Joan­na Poź­ni­ak.

Joan­na holds a Bachelor’s degree in Mol­e­c­u­lar Biol­o­gy and an inter­na­tion­al Master’s degree in Biotech­nol­o­gy from Adam Mick­iewicz Uni­ver­si­ty in Poz­nań, Poland. She com­plet­ed her PhD at the Uni­ver­si­ty of Leeds as part of the Marie Skłodows­ka-Curie Ear­ly Train­ing Net­work (MEL­GEN), where her research focused on char­ac­ter­iz­ing immune infil­tra­tion across a large cohort of pri­ma­ry melanoma tran­scrip­tomes using bioin­for­mat­ics and sta­tis­ti­cal approaches. 

She is cur­rent­ly a Senior Post­doc­tor­al Researcher in Bioin­for­mat­ics at the Marine Lab (VIB – KU Leu­ven, Bel­gium), sup­port­ed by Marie Skłodows­ka-Curie and STK Bel­gian fel­low­ships. Her work focus­es on melanoma het­ero­gene­ity and respons­es to immunother­a­py, employ­ing sin­gle-cell sequenc­ing and spa­tial tran­scrip­tomics. Her con­tri­bu­tions have been rec­og­nized with the pres­ti­gious Soci­ety for Melanoma Research (SMR) Young Inves­ti­ga­tor Award.

Joanna Poźniak | Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Joan­na Poź­ni­ak, KU Leu­ven, BELGIUM

Read the Abstracts from Our Invit­ed Speakers

Can­cer Biology

Can­cer Neuroscience

Can­cer Therapy